Qiao Ning, Li Chuzhong, Zheng Fei, Zhang Lingling, Ma Guofo, Jia Yanfei, Cai Kefan, Chen Xuzhu, Lu Pengwei, Zhang Yazhuo, Gui Songbai
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Beijing, 100070, China.
Department of Cell Biology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Neurosurg Rev. 2024 Dec 27;48(1):8. doi: 10.1007/s10143-024-03170-w.
Although craniopharyngiomas are rare benign brain tumors primarily managed by surgery, they are often burdened by a poor prognosis due to tumor recurrence and long-term morbidity. In recent years, BRAF-targeted therapy has been promising, showing potential as an adjuvant or neoadjuvant approach. Therefore, we aim to develop and validate a radiomics nomogram for preoperative prediction of BRAF mutation in craniopharyngiomas. A total of 398 patients with craniopharyngioma (training cohort: n = 278; validation cohort: n = 120) were retrospectively reviewed. We extracted 851 radiomic features from MRI images and adopted a support vector machine (SVM) classifier to develop a radiomic model. Also, a clinical-radiomics nomogram was constructed based on a multivariable logistic regression analysis. The performance of the nomogram was evaluated by its discrimination, calibration, and clinical utility. The radiomic model using the SVM based on three selected features showed good discrimination in the training and validation cohorts (area under the curve [AUC], 0.941 and 0.945, respectively). A higher Rad-score, smaller tumor volume, and homogenous enhancement were demonstrated as independent predictors of BRAF mutation in craniopharyngioma. The nomogram incorporating the Rad-score and clinical-radiological factors exhibited AUCs of 0.958 (95% CI, 0.936-0.980) and 0.956 (95% CI, 0.921-0.991) in the training and validation cohorts, respectively, showing good clinical benefit and calibration. The radiomics nomogram could provide an accurate, non-invasive preoperative prediction of BRAF mutation in craniopharyngioma and may provide potential guidance for the preoperative administration of BRAF mutation inhibitors and promote personalized treatment. Further prospective validation is still needed.
尽管颅咽管瘤是罕见的良性脑肿瘤,主要通过手术治疗,但由于肿瘤复发和长期并发症,其预后往往较差。近年来,BRAF靶向治疗前景广阔,显示出作为辅助或新辅助治疗方法的潜力。因此,我们旨在开发并验证一种用于术前预测颅咽管瘤BRAF突变的放射组学列线图。我们对398例颅咽管瘤患者(训练队列:n = 278;验证队列:n = 120)进行了回顾性分析。我们从MRI图像中提取了851个放射组学特征,并采用支持向量机(SVM)分类器建立了放射组学模型。此外,基于多变量逻辑回归分析构建了临床-放射组学列线图。通过辨别力、校准度和临床实用性对列线图的性能进行评估。基于三个选定特征的SVM放射组学模型在训练队列和验证队列中均显示出良好的辨别力(曲线下面积[AUC]分别为0.941和0.945)。较高的Rad评分、较小的肿瘤体积和均匀强化被证明是颅咽管瘤BRAF突变的独立预测因素。纳入Rad评分和临床-放射学因素的列线图在训练队列和验证队列中的AUC分别为0.958(95%CI,0.936 - 0.980)和0.956(95%CI,0.921 - 0.991),显示出良好的临床效益和校准度。放射组学列线图可以对颅咽管瘤的BRAF突变进行准确、无创的术前预测,并可能为术前使用BRAF突变抑制剂提供潜在指导,促进个性化治疗。仍需要进一步的前瞻性验证。